Lantheus (LNTH) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.
Thursday, Feb. 26, 2026 at 8 a.m. ET
Lantheus (NASDAQ:LNTH) emphasized a strategic pivot to PET radiodiagnostics, highlighted by the divestiture of its SPECT business on Jan. 1, 2026, and the acquisitions of Neuraceq and OCTEVY, with four near-term FDA approval catalysts identified. Management stated that 2026 will be a year of investment in commercialization infrastructure, with the majority of revenue growth acceleration and portfolio diversification expected in 2027 following late-year product launches. The company will also optimize its cost base and reassess its radiotherapeutic pipeline for value-maximizing externalization or partnerships, indicating a restrained near-term M&A approach.
Source Fool.com
